

# Giuliana Decorti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7044089/publications.pdf>

Version: 2024-02-01

155  
papers

2,746  
citations

186209

28  
h-index

254106

43  
g-index

156  
all docs

156  
docs citations

156  
times ranked

3774  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytofluorimetric assay to investigate variability in blinatumomab in vitro response. <i>Frontiers in Bioscience</i> , 2022, 27, 039.	0.8	0
2	Antibiotics and Liver Cirrhosis: What the Physicians Need to Know. <i>Antibiotics</i> , 2022, 11, 31.	1.5	16
3	Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: $\beta$ -Lactam/ $\beta$ -Lactamase Inhibitors in Combination and Cefiderocol – An All-Inclusive Guide for Clinicians. <i>Pharmaceuticals</i> , 2022, 15, 463.	1.7	13
4	Patient-derived organoids for therapy personalization in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2022, 28, 2636-2653.	1.4	7
5	Atomic Force Microscopy Application for the Measurement of Infliximab Concentration in Healthy Donors and Pediatric Patients with Inflammatory Bowel Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 948.	1.1	3
6	Genome wide association studies for treatment-related adverse effects of pediatric acute lymphoblastic leukemia. <i>WIREs Mechanisms of Disease</i> , 2021, 13, e1509.	1.5	4
7	Ergothioneine, a dietary amino acid with a high relevance for the interpretation of label-free surface enhanced Raman scattering (SERS) spectra of many biological samples. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2021, 246, 119024.	2.0	20
8	Microbiota and Drug Response in Inflammatory Bowel Disease. <i>Pathogens</i> , 2021, 10, 211.	1.2	23
9	Gender May Influence the Immunosuppressive Actions of Prednisone in Young Patients With Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2021, 12, 673068.	2.2	4
10	Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease. <i>Clinical and Translational Science</i> , 2021, 14, 2184-2192.	1.5	11
11	In Vitro Effects of Sulforaphane on Interferon-Driven Inflammation and Exploratory Evaluation in Two Healthy Volunteers. <i>Molecules</i> , 2021, 26, 3602.	1.7	2
12	Responses of patients with juvenile idiopathic arthritis to methotrexate: a genomic outlook. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1131-1142.	1.3	0
13	Insights into the cellular pharmacokinetics and pharmacodynamics of thiopurine antimetabolites in a model of human intestinal cells. <i>Chemico-Biological Interactions</i> , 2021, 347, 109624.	1.7	2
14	Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients. <i>Clinical and Translational Science</i> , 2021, 14, 964-975.	1.5	13
15	Biomarkers for gastrointestinal adverse events related to thiopurine therapy. <i>World Journal of Gastroenterology</i> , 2021, 27, 6348-6356.	1.4	2
16	A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias. <i>Frontiers in Pharmacology</i> , 2021, 12, 749361.	1.6	4
17	Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. <i>Clinical and Translational Science</i> , 2020, 13, 238-259.	1.5	12
18	PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 415-425.	0.9	15

#	ARTICLE	IF	CITATIONS
19	Induced pluripotent stem cells to model adverse drug reactions in pediatric patients. <i>Pharmacogenomics</i> , 2020, 21, 975-978.	0.6	0
20	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 361-374.	1.1	7
21	Pharmacogenomics of Antibiotics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5975.	1.8	16
22	MOO06INFLAMMASOME ACTIVATOR NLRP3 HYPOMETHYLATION IS ASSOCIATED WITH GLUCOCORTICOID RESISTANCE IN PATIENTS WITH IDIOPATHIC NEPHROTIC SYNDROME. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
23	A patent review of anticancer glucocorticoid receptor modulators (2014-present). <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 313-324.	2.4	3
24	Biomarkers and Precision Therapy for Primary Immunodeficiencies: An In Vitro Study Based on Induced Pluripotent Stem Cells From Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 358-367.	2.3	8
25	Clinical Application of Thiopurine Pharmacogenomics in Pediatrics. <i>Current Drug Metabolism</i> , 2020, 21, 53-62.	0.7	6
26	Long Non-Coding RNA GAS5 and Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients with IBD. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5280.	1.8	24
27	MIF plasma level as a possible tool to predict steroid responsiveness in children with idiopathic nephrotic syndrome. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1675-1683.	0.8	9
28	Generation of 3 clones of induced pluripotent stem cells (iPSCs) from a patient affected by Crohn's disease. <i>Stem Cell Research</i> , 2019, 40, 101548.	0.3	1
29	Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, 37-44.	0.9	41
30	Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 527-539.	1.5	20
31	Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants. <i>Genes</i> , 2019, 10, 277.	1.0	13
32	Expression pattern of long non-coding RNA growth arrest-specific 5 in the remission induction therapy in childhood acute lymphoblastic leukemia. <i>Journal of Medical Biochemistry</i> , 2019, 38, 292-298.	0.7	22
33	Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 69, 474-479.	0.9	14
34	Pharmacogenetics of thiopurines. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 256-270.	0.9	6
35	Role of tristetraprolin phosphorylation in paediatric patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 5918-5925.	1.4	4
36	Induced pluripotent stem cells for therapy personalization in pediatric patients: Focus on drug-induced adverse events. <i>World Journal of Stem Cells</i> , 2019, 11, 1020-1044.	1.3	14

#	ARTICLE	IF	CITATIONS
37	Imidazo[2,1- <i>b</i> ]benzothiazol Derivatives as Potential Allosteric Inhibitors of the Glucocorticoid Receptor. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 339-344.	1.3	4
38	SERS of cells: What can we learn from cell lysates?. <i>Analytica Chimica Acta</i> , 2018, 1005, 93-100.	2.6	32
39	Induced Pluripotent Stem Cells as a Model for Therapy Personalization of Pediatric Patients: Disease Modeling and Drug Adverse Effects Prevention. <i>Current Medicinal Chemistry</i> , 2018, 25, 2826-2839.	1.2	7
40	Pharmacogenetics of treatments for inflammatory bowel disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1209-1223.	1.5	27
41	Novel motif of variable number of tandem repeats in <i>TPMT</i> promoter region and evolutionary association of variable number of tandem repeats with <i>TPMT*3</i> alleles. <i>Pharmacogenomics</i> , 2018, 19, 1311-1322.	0.6	10
42	High-Throughput Sequencing of microRNAs in Glucocorticoid Sensitive Paediatric Inflammatory Bowel Disease Patients. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1399.	1.8	15
43	Role of the Long Non-coding RNA Growth Arrest-specific 5 in Glucocorticoid Response in Children with Inflammatory Bowel Disease. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 87-93.	1.2	41
44	Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease. <i>Current Medicinal Chemistry</i> , 2018, 25, 2855-2871.	1.2	9
45	Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. <i>Pharmacogenomics Journal</i> , 2017, 17, 4-10.	0.9	28
46	Multicentric Case-Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 628-634.	0.9	11
47	Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1382-1389.e1.	2.4	17
48	Pharmacokinetics and pharmacodynamics of thiopurines in an <i>in vitro</i> model of human hepatocytes: Insights from an innovative mass spectrometry assay. <i>Chemico-Biological Interactions</i> , 2017, 275, 189-195.	1.7	3
49	Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1810-1816.	0.9	11
50	Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives. <i>Current Medicinal Chemistry</i> , 2017, 24, 1050-1065.	1.2	15
51	Role of inosine triphosphate pyrophosphatase gene variant on fever incidence during zidovudine antiretroviral therapy. <i>Genetics and Molecular Research</i> , 2017, 16, .	0.3	2
52	Glucocorticoid Receptor Interacting Co-regulators: Putative Candidates for Future Drug Targeting Therapy. <i>Mini-Reviews in Medicinal Chemistry</i> , 2017, 17, 657-666.	1.1	2
53	<i>In vitro</i> sensitivity to methylprednisolone is associated with clinical response in pediatric idiopathic nephrotic syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 268-274.	2.3	5
54	Differential expression of <i>GAS</i> 5 in rapamycin-induced reversion of glucocorticoid resistance. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 602-605.	0.9	15

#	ARTICLE	IF	CITATIONS
55	Carbamazepine-induced thrombocytopenic purpura in a child: Insights from a genomic analysis. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 59, 97-99.	0.6	2
56	<i>SXR</i> rs3842689: a prognostic factor for steroid sensitivity or resistance in pediatric idiopathic nephrotic syndrome. <i>Pharmacogenomics</i> , 2016, 17, 1227-1233.	0.6	9
57	Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes. <i>Molecular Medicine Reports</i> , 2016, 14, 574-582.	1.1	1
58	Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress. <i>Current Drug Metabolism</i> , 2016, 17, 542-549.	0.7	13
59	Emerging molecular mechanisms underlying cancer metastasis: the rising role of the long non-coding RNA GAS5. <i>Translational Cancer Research</i> , 2016, 5, S827-S830.	0.4	2
60	Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1739-1749.	0.9	28
61	Patients' Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?. <i>Current Drug Metabolism</i> , 2015, 17, 91-98.	0.7	7
62	Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children. <i>International Journal of Molecular Sciences</i> , 2015, 16, 18601-18627.	1.8	6
63	Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response. <i>Current Molecular Medicine</i> , 2015, 15, 94-99.	0.6	42
64	Glucocorticoids in Pediatric Gastrointestinal Disorders. , 2015, , 105-121.		0
65	Genetic determinants for methotrexate response in juvenile idiopathic arthritis. <i>Frontiers in Pharmacology</i> , 2015, 6, 52.	1.6	13
66	5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis. <i>Rheumatology International</i> , 2015, 35, 619-627.	1.5	14
67	Role of Oxidative Stress Mediated by Glutathione-<i>S</i>-transferase in Thiopurinesâ€™ Toxic Effects. <i>Chemical Research in Toxicology</i> , 2015, 28, 1186-1195.	1.7	12
68	Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome. <i>Pharmacogenomics</i> , 2015, 16, 1631-1648.	0.6	23
69	Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: Effect of N-acetyl transferase polymorphisms. <i>World Journal of Gastroenterology</i> , 2015, 21, 3571.	1.4	11
70	Failure of interferon- $\beta$ pre-treated mesenchymal stem cell treatment in a patient with Crohnâ€™s disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 4379.	1.4	21
71	<i>TNF-</i> SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype. <i>Pharmacogenomics</i> , 2014, 15, 619-627.	0.6	2
72	Deletion of Glutathione-S-Transferase M1 Reduces Azathioprine Metabolite Concentrations in Young Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 43-51.	1.1	43

#	ARTICLE	IF	CITATIONS
73	Fate of Lymphocytes after Withdrawal of Tofacitinib Treatment. PLoS ONE, 2014, 9, e85463.	1.1	16
74	Pharmacogenetics of azathioprine in inflammatory bowel disease: A role for glutathione-S-transferase?. World Journal of Gastroenterology, 2014, 20, 3534.	1.4	41
75	The effect of nonsurgical periodontal treatment on the severity of drug-induced gingival overgrowth in transplant patients. Quintessence International, 2014, 45, 115-24.	0.3	4
76	Research Highlights: Highlights from the latest articles in acute lymphoblastic leukemia pharmacogenomics. Pharmacogenomics, 2013, 14, 235-239.	0.6	2
77	Effect of Thalidomide on Clinical Remission in Children and Adolescents With Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2013, 310, 2164.	3.8	85
78	MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. World Journal of Gastroenterology, 2013, 19, 7947.	1.4	26
79	Pharmacogenomic Approaches for Tailored Anti-Leukemic Therapy in Children. Current Medicinal Chemistry, 2013, 20, 2237-2253.	1.2	7
80	Effect of periodontal therapy on the course of cyclosporin-induced gingival overgrowth: role of ABCB1 and PAI-1 gene polymorphisms. Quintessence International, 2013, 44, 249-60.	0.3	1
81	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Human Molecular Genetics, 2012, 21, 4793-4804.	1.4	56
82	Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases. Current Pharmaceutical Design, 2012, 18, 5766-5775.	0.9	10
83	Glutathione <i>S</i> -transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. Pharmacogenomics, 2012, 13, 1905-1916.	0.6	16
84	Association between <i>Bcl</i> polymorphism in the <i>NR3C1</i> gene and <i>in vitro</i> individual variations in lymphocyte responses to methylprednisolone. British Journal of Clinical Pharmacology, 2012, 73, 651-655.	1.1	32
85	The effect of clodronate on a mevalonate kinase deficiency cellular model. Inflammation Research, 2012, 61, 1363-1367.	1.6	3
86	The cytotoxic effect of palytoxin on Caco-2 cells hinders their use for <i>in vitro</i> absorption studies. Food and Chemical Toxicology, 2012, 50, 206-211.	1.8	26
87	Letter: <i>TPMT</i> activity and age in IBD patients. Alimentary Pharmacology and Therapeutics, 2012, 35, 966-967.	1.9	2
88	Multilocus Genotypes of Relevance for Drug Metabolizing Enzymes and Therapy with Thiopurines in Patients with Acute Lymphoblastic Leukemia. Frontiers in Genetics, 2012, 3, 309.	1.1	13
89	Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes. International Immunopharmacology, 2011, 11, 2242-2245.	1.7	8
90	Genetic Predictors of Glucocorticoid Response in Pediatric Patients With Inflammatory Bowel Diseases. Journal of Clinical Gastroenterology, 2011, 45, e1-e7.	1.1	54

#	ARTICLE	IF	CITATIONS
91	Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-fluorouracil independently of microsatellite instability. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 201-210.	1.2	22
92	The Farnesyltransferase Inhibitors Tipifarnib and Lonafarnib Inhibit Cytokines Secretion in a Cellular Model of Mevalonate Kinase Deficiency. <i>Pediatric Research</i> , 2011, 70, 78-82.	1.1	20
93	Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 1095.	1.4	116
94	Decreased cholesterol levels reflect a consumption of anti-inflammatory isoprenoids associated with an impaired control of inflammation in a mouse model of mevalonate kinase deficiency. <i>Inflammation Research</i> , 2010, 59, 335-338.	1.6	14
95	Selective resistance to different glucocorticoids in severe autoimmune disorders. <i>Clinical Immunology</i> , 2010, 134, 313-319.	1.4	8
96	Expression of bilitranslocase in the vascular endothelium and its function as a flavonoid transporter. <i>Cardiovascular Research</i> , 2010, 85, 175-183.	1.8	55
97	Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 599-602.	0.6	19
98	Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: In vitro and in vivo approaches. <i>Pharmacological Research</i> , 2010, 61, 506-510.	3.1	17
99	Oxidative stress-based cytotoxicity of delphinidin and cyanidin in colon cancer cells. <i>Archives of Biochemistry and Biophysics</i> , 2010, 501, 151-157.	1.4	115
100	Fasting Increases Tobramycin Oral Absorption in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1644-1646.	1.4	14
101	Glutathione-S-transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 483-491.	0.8	14
102	Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: Role of polymorphisms of genes involved in glucocorticoid response. <i>Pediatric Blood and Cancer</i> , 2009, 53, 984-991.	0.8	38
103	Carbamazepine Hypersensitivity Syndrome Triggered by a Human Herpes Virus Reactivation in a Genetically Predisposed Patient. <i>International Archives of Allergy and Immunology</i> , 2009, 149, 173-177.	0.9	13
104	Interruption of Mesalamine and Reduction of the Blood Concentration of the Active Metabolites of Azathioprine: Possible Causes of Ulcerative Colitis Relapse. <i>Digestive Diseases and Sciences</i> , 2008, 53, 3246-3249.	1.1	10
105	Role of <i>MDR1</i> gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients. <i>Journal of Periodontal Research</i> , 2008, 43, 665-672.	1.4	17
106	Role of ABC Transporters in the BeWo Trophoblast Cell Line. <i>Toxicology Mechanisms and Methods</i> , 2008, 18, 763-769.	1.3	7
107	In Vitro Effects of Yessotoxin on a Primary Culture of Rat Cardiomyocytes. <i>Toxicological Sciences</i> , 2008, 106, 392-399.	1.4	29
108	Natural Isoprenoids are Able to Reduce Inflammation in a Mouse Model of Mevalonate Kinase Deficiency. <i>Pediatric Research</i> , 2008, 64, 177-182.	1.1	54



#	ARTICLE	IF	CITATIONS
109	ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer. <i>Anticancer Research</i> , 2008, 28, 3921-8.	0.5	20
110	Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease. <i>Gut</i> , 2007, 56, 1319-1320.	6.1	50
111	Inflammatory bowel disease. <i>Lancet, The</i> , 2007, 370, 316-317.	6.3	0
112	Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 57-64.	0.9	65
113	Thiopurine S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1083-1084.	1.9	6
114	St John's wort modulation and developmental expression of multidrug transporters in the rat. <i>Phytotherapy Research</i> , 2006, 20, 468-473.	2.8	16
115	Prevalence of Methylenetetrahydrofolate Reductase Polymorphisms in Young Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2006, 51, 474-479.	1.1	15
116	Osteonecrosis of the hip after short courses of oral and inhaled steroids in a child with an increased number of glucocorticoid receptors. <i>European Journal of Pediatrics</i> , 2006, 165, 913-915.	1.3	6
117	Glucocorticoid resistance in a girl with Takayasu's arteritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 689-691.	0.5	7
118	Uptake of bilirubin into HepG2 cells assayed by thermal lens spectroscopy. Function of bilitranslocase. <i>FEBS Journal</i> , 2005, 272, 5522-5535.	2.2	54
119	Determination of bilirubin by thermal lens spectrometry and studies of its transport into hepatic cells. <i>European Physical Journal Special Topics</i> , 2005, 125, 717-720.	0.2	6
120	Hepatic uptake of grape anthocyanins and the role of bilitranslocase. <i>Food Research International</i> , 2005, 38, 953-960.	2.9	42
121	TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2005, 37, 940-945.	0.4	29
122	Toxicity of <i>Hypericum perforatum</i> (St. John's wort) administered during pregnancy and lactation in rats. <i>Toxicology and Applied Pharmacology</i> , 2004, 200, 201-205.	1.3	44
123	Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. <i>European Journal of Pharmacology</i> , 2004, 483, 19-28.	1.7	42
124	Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. <i>Cancer Letters</i> , 2004, 205, 107-115.	3.2	13
125	Hemolytic Effects of Water-Soluble Fullerene Derivatives. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6711-6715.	2.9	114
126	Bodipy-FL-Verapamil: A Fluorescent Probe for the Study of Multidrug Resistance Proteins. <i>Analytical Cellular Pathology</i> , 2004, 26, 3-11.	0.7	6



#	ARTICLE	IF	CITATIONS
127	Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. <i>Development Growth and Differentiation</i> , 2003, 45, 377-387.	0.6	53
128	The Fluorescent Probe Bodipy-FL-Verapamil Is a Substrate for Both P-glycoprotein and Multidrug Resistance-related Protein (MRP)-1. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 731-734.	1.3	29
129	Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin. <i>Life Sciences</i> , 2002, 71, 3109-3119.	2.0	28
130	Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. <i>Journal of Pineal Research</i> , 2001, 31, 206-213.	3.4	37
131	Expression and function of P-glycoprotein and absence of multidrug resistance-related protein in rat and beige mouse peritoneal mast cells. <i>The Histochemical Journal</i> , 2001, 33, 259-266.	0.6	5
132	Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. <i>Biochemical Pharmacology</i> , 2001, 61, 61-66.	2.0	11
133	Biochemical and Microscopic Evidence for the Internalization of Drug-Containing Mast Cell Granules by Macrophages and Smooth Muscle Cells. <i>Toxicology and Applied Pharmacology</i> , 2000, 169, 269-275.	1.3	8
134	Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport. <i>The Histochemical Journal</i> , 1999, 31, 635-643.	0.6	21
135	Endocytosis of gentamicin in a proximal tubular renal cell line. <i>Life Sciences</i> , 1999, 65, 1115-1124.	2.0	15
136	Stimulation of Rat Peritoneal Mast Cells Induces Phagocytosis of Adriamycin by Rat Peritoneal Macrophages. <i>Biotechnic and Histochemistry</i> , 1998, 73, 82-91.	0.7	0
137	Binding of Aminoglycoside Antibiotics by Degranulating Mast Cells. <i>Chemotherapy</i> , 1997, 43, 36-42.	0.8	3
138	Adriamycin Binds to the Matrix of Secretory Granules during Mast Cell Exocytosis. <i>Biotechnic and Histochemistry</i> , 1997, 72, 111-116.	0.7	6
139	Identification of P-glycoprotein at the membrane of mast cell secretory granules. An immunofluorescence and protein A-gold electron microscopical investigation. <i>The Histochemical Journal</i> , 1997, 29, 193-198.	0.6	11
140	Adriamycin-induced histamine release from heart tissue in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 363-366.	1.1	12
141	Effect of sodium nedocromil on histamine release and toxicity induced by adriamycin. <i>Current Therapeutic Research</i> , 1994, 55, 1238-1246.	0.5	0
142	Effect of Neomycin and Other Aminoglycosides on Adriamycin Uptake in Rat Peritoneal Mast Cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1993, 73, 341-343.	0.0	0
143	Evidence of an adriamycin binding site in the secretory granules of the mast cell. <i>Chemico-Biological Interactions</i> , 1991, 78, 97-108.	1.7	4
144	Amelioration of 4 $\beta$ -epidoxorubicin-induced cardiotoxicity by sodium cromoglycate. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 361-368.	0.9	11

#	ARTICLE	IF	CITATIONS
145	Effect of ketotifen on adriamycin toxicity: Role of histamine. <i>Cancer Letters</i> , 1988, 39, 145-152.	3.2	7
146	Differential Effects of Sodium Cromoglycate on Adriamycin-Induced Histamine Release from Isolated Rat and Mouse Mast Cells. <i>International Journal of Immunopathology and Pharmacology</i> , 1988, 1, 115-118.	1.0	0
147	Dimethyl sulfoxide inhibits histamine release induced by various chemicals. <i>Agents and Actions</i> , 1987, 20, 17-28.	0.7	12
148	Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. <i>Clinical and Experimental Metastasis</i> , 1987, 5, 27-34.	1.7	6
149	Characterization of histamine secretion induced by anthracyclines in rat peritoneal mast cells. <i>Biochemical Pharmacology</i> , 1986, 35, 1939-1942.	2.0	28
150	Effect of polyethylene glycol 400 on adriamycin induced histamine release. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1986, 22, 793-799.	0.9	4
151	Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo. <i>British Journal of Cancer</i> , 1986, 54, 743-748.	2.9	34
152	Enhancement of paracetamol induced hepatotoxicity by prior treatment with carboxymethylcellulose. <i>Pharmacological Research Communications</i> , 1984, 16, 313-318.	0.2	4
153	Effects of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1984, 20, 287-289.	0.9	3
154	Effect of polyethylene glycol 400 on adriamycin toxicity in mice. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1984, 20, 405-410.	0.9	7
155	Enhancement of adriamycin toxicity by carboxymethylcellulose in mice. <i>Toxicology and Applied Pharmacology</i> , 1983, 71, 288-293.	1.3	6